OCA
GYRE icon

Octagon Capital Advisors’s Gyre Therapeutics GYRE Stock Holding History

Octagon Capital Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.29M Buy
+954,416
New +$6.5M 0.57% 23

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Octagon Capital Advisors's GYRE Position: Q2 2026 in Review

Octagon Capital Advisors opened a new position in Gyre Therapeutics (GYRE) in Q2 2026: 954,416 shares worth $6.29M. The stake represents 0.57% of the portfolio and ranks #23 among its holdings.

57 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Octagon Capital Advisors held 954,416 shares of Gyre Therapeutics worth $6.29M as of Q2 2026.
  • Gyre Therapeutics was a new Octagon Capital Advisors position in Q2 2026.
  • Gyre Therapeutics made up 0.57% of Octagon Capital Advisors's portfolio in Q2 2026, its #23 holding.
  • 57 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.